论文部分内容阅读
目的研究紫杉醇联合顺铂对晚期卵巢癌患者免疫系统及生活质量的影响。方法选取2013年6月—2016年7月收治的晚期卵巢癌患者54例作为研究对象。随机分为对照组和观察组各27例。对照组予以顺铂治疗,观察组予以紫杉醇联合顺铂治疗。统计对比两组治疗效果,检测比较治疗前后两组免疫系统相关指标(CD4~+CD25~+、CD4~+/CD8~+)水平变化及生活质量评分变化情况。计量资料采用t检验,计数资料采用χ~2检验,P<0.05为差异有统计学意义。结果治疗后,观察组治疗总有效率为85.19%,明显高于对照组的59.26%,差异有统计学意义(P<0.05)。治疗后,观察组CD4~+CD25~+、CD4~+/CD8~+水平分别为(1.47±0.73)%、(1.82±0.36)%,均明显优于对照组的(1.89±0.65)%、(1.47±0.23)%,差异均有统计学意义(均P<0.05)。治疗后,观察组社会功能、情绪功能、认知功能、躯体功能、角色功能评分分别为(3.42±1.03)、(7.68±1.73)、(5.67±1.23)、(8.67±1.73)、(4.93±0.73)分,均高于对照组的(2.68±0.89)、(6.35±1.46)、(4.67±1.01)、(7.03±1.62)、(4.56±0.58)分,差异均有统计学意义(均P<0.05)。结论紫杉醇联合顺铂治疗晚期卵巢癌患者临床疗效显著,可明显提高患者生活质量,并改善其免疫功能。
Objective To study the effects of paclitaxel combined with cisplatin on the immune system and quality of life in patients with advanced ovarian cancer. Methods 54 patients with advanced ovarian cancer who were admitted from June 2013 to July 2016 were selected as the research object. Randomly divided into control group and observation group of 27 cases. The control group was treated with cisplatin, and the observation group was treated with paclitaxel combined with cisplatin. The therapeutic effects were compared between the two groups. The levels of immune-related indicators (CD4 ~ + CD25 ~ +, CD4 ~ + / CD8 ~ +) and quality of life changes were compared between the two groups before and after treatment. Measurement data using t test, count data using χ ~ 2 test, P <0.05 for the difference was statistically significant. Results After treatment, the total effective rate of the observation group was 85.19%, which was significantly higher than that of the control group (59.26%), the difference was statistically significant (P <0.05). After treatment, the levels of CD4 ~ + CD25 ~ + and CD4 ~ + / CD8 ~ + in the observation group were significantly higher than those in the control group (1.47 ± 0.73)% and (1.47 ± 0.23)%, respectively, with significant difference (all P <0.05). After treatment, the scores of social function, emotional function, cognitive function, body function and function of the observation group were (3.42 ± 1.03), (7.68 ± 1.73), (5.67 ± 1.23), (8.67 ± 1.73), (4.93 ± 0.73) were higher than that of the control group (2.68 ± 0.89), (6.35 ± 1.46), (4.67 ± 1.01), (7.03 ± 1.62) and (4.56 ± 0.58) respectively, the difference was statistically significant <0.05). Conclusion Paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer patients with significant clinical efficacy, can significantly improve the quality of life of patients and improve their immune function.